ArticleEmerging infectious diseases2025
Emergence of Flucytosine-Resistant Candida tropicalis Clade, the Netherlands.
Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genomic insights into a clade-specificmBio · 2026Article
- Multi-omics analysis reveals the critical role of gut microbiota related tryptophan and glutathione metabolism in sepsis-associated encephalopathy.BMC microbiology · 2026Article
- Antifungal Susceptibility and Resistance-Associated Gene Expression in NosocomialJournal of fungi (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida tropicalis is the second most virulent Candida species after C. albicans. Previous studies from the Netherlands and France reported a notable reduction in susceptibility to flucytosine (5-FC) in a substantial proportion of C. tropicalis isolates. We investigated epidemiologic patterns of C. tropicalis isolates in the Netherlands and the genetic mechanisms driving widespread non-wild-type (WT) 5-FC resistance. We conducted antifungal susceptibility testing and used advanced molecular techniques, including short tandem repeat genotyping and whole-genome sequencing paired with single-nucleotide polymorphism analysis, to analyze 250 C. tropicalis isolates collected across the Netherlands during 2012-2022. Our findings revealed the rapid emergence of a 5-FC-resistant, non-WT C. tropicalis clade, accounting for >40% of all C. tropicalis isolates by 2022. Genomic analysis identified a homozygous nonsense mutation in the FCY2 gene, which was exclusive to this non-WT population. Continued surveillance efforts are needed to detect and prevent the spread of drug-resistant Candida species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.